Martha Chekenya Enger
First-class Honours BSc Psychology from the University of Westminster, London, UK. Master of Science in Neuroscience from The Institute of Psychiatry/King's College, University of London. PhD at King's, Guy's, St Thomas' School of Medicine and Dentistry, University of London. Dr Philos at the University of Bergen, Norway.
The Brain Tumour Immunology and Therapy Group is focussed on biomedical research to study malignant brain tumours, the role of the NG2 proetoglycan in tumour progression and response to therapy. Glioblastoma is a highly heterogenous tumour and we have barely begun to reveal its complexicity. We appreciate now, more than ever that even the most focussed single therapy will inevitably elicit resistance and treatment failure.Longlasting therapy will only be achieved by combining multiple targets, thus our group is highly motivated to identify new therapeutic targets that mediate treatment resistance and poor survival in patients. We use multidisciplinary approaches such as patient biobanks and biopsy based animal models, proteomics, functional magnetic resonance imaging (employing physical properties of tissues to describe biological processes), flow cytometry, and standard molecular and cell biology methods.
The long term vision of the group is to develop novel immunotherapy strategies that may be applied in combination to the standrd treatment of GBM patients in the clinic.